Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGB 15025

Next Previous
Drug Profile

BGB 15025

Alternative Names: BGB-15025

Latest Information Update: 14 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Developer BeOne Medicines
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 27 Dec 2024 Chemical structure information added.
  • 01 Aug 2024 BGB 15025 is still in phase I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, combination therapy) in New Zealand, USA, Australia, China and South Korea (PO) (NCT04649385)
  • 13 Jun 2024 Pharmacodynamics data from a preclinical trials in cancer presented at the 29th Congress of the European Haematology Association (EHA-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top